Solara Active Pharma Sciences (NSE:SOLARAPP1) Research & Development: ₹0 Mil (TTM As of Mar. 2026)


NSE:SOLARAPP1 Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
67 GF Score
Price ₹267.45
GF Value ₹263.62
! 3 Warning Signs
View Full Analysis

What is Solara Active Pharma Sciences Research & Development?

Solara Active Pharma Sciences NSE:SOLARAPP1 67 Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SOLARAPP1 with a GF Score™ of 67/100 and a GF Value™ of ₹263.62. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Solara Active Pharma Sciences's Research & Development for the three months ended in Mar. 2026 was ₹0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil.

Solara Active Pharma Sciences  (NSE:SOLARAPP1) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Solara Active Pharma Sciences Research & Development Related Terms

Solara Active Pharma Sciences Research & Development Historical Data

* Premium members only.

The historical data trend for Solara Active Pharma Sciences's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Solara Active Pharma Sciences Research & Development Chart

Solara Active Pharma Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Solara Active Pharma Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SOLARAPP1
67GF Score
Solara Active Pharma Sciences Ltd NSE:SOLARAPP1
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Solara Active Pharma Sciences Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0 Mil mean?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a Research & Development of ₹0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Solara Active Pharma Sciences and its competitors.
Is Solara Active Pharma Sciences' Research & Development too high?
Solara Active Pharma Sciences' current Research & Development is ₹0 Mil. Overall, Solara Active Pharma Sciences has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Research & Development compare to ZTS and UTHR?
Solara Active Pharma Sciences' Research & Development of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Solara Active Pharma Sciences and its competitors. Solara Active Pharma Sciences's current Research & Development is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Solara Active Pharma Sciences (NSE:SOLARAPP1) has a current Research & Development of ₹0 Mil. The stock's GF Value™ is ₹263.62, compared to a current price of ₹267.45 — trading 1.5% above its estimated fair value. The current Research & Development is ₹0 Mil. Solara Active Pharma Sciences' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Solara Active Pharma Sciences (NSE:SOLARAPP1), the current Research & Development is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Solara Active Pharma Sciences (NSE:SOLARAPP1) Overvalued in 2026?

Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be overvalued. The current stock price of ₹267.45 is trading 1.5% above its estimated GF Value™ of ₹263.62.

Key valuation signals for NSE:SOLARAPP1:

  • Research & Development: ₹0 Mil
  • GF Value™: ₹263.62 vs. price of ₹267.45 (1.5% above fair value)
  • GF Score™: 67/100 with 3 warning signs

No single metric tells the full story. See the NSE:SOLARAPP1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Solara Active Pharma Sciences Business Description

Other Exchanges SOLARA:India541540:India
Address Phase II - CSIR Road, Module No. 601, 602, 603, Ticel Bio Park, Taramani, Chennai, TN, IND, 600113
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
67GF Score

Get the complete analysis for NSE:SOLARAPP1

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹267.45
Price
₹263.62
GF Value